Vapotherm Blog

Can I Use Cannulaide® with Vapotherm®?

Cannulaide® is a transparent adhesive designed to relieve irritation of the nares in neonates who are placed on nasal CPAP. The product creates an air seal to support the pressure mechanism of CPAP while ensuring that the cannula prongs do not fully occlude the neonate’s nares and thereby don’t lead to a potential Hospital Acquired Pressure Injury (HAPI).

Growing Evidence Suggests High Flow Nasal Cannula Is Safe and Effective Tool for Children with Asthma Presenting in the Emergency Department

Asthma is one of the most pervasive chronic pediatric diseases, accounting for about 1.6 million emergency department (ED) visits annually and showing an upward trend. Emergency clinicians have been suspecting that High Flow Nasal Cannula (HFNC) could be a safe and effective tool in the treatment of children with asthma, but research on the subject has been sparse.

Transforming Rehabilitation from a Place to a Philosophy of Care to Improve Clinical and Economic Outcomes

The increased acuity of the ICU patient over the years and development of pharmaceuticals for sedation and technological advancements in life support have played a role in the challenge of providing early mobility for this patient population.

What are Ventilator-Associated Pneumonias/Ventilator-Associated Events and How to Reduce Their Prevalence in Your Hospital

It is difficult to pin down the exact prevalence of Ventilator-Associated Pneumonia (VAP)/Ventilator-Associated Events (VAE), but it is widely agreed that they are among the most common nosocomial events in the ICU, leading to decreased patient outcomes and increased length of stay.

What’s the Difference Between Vapotherm® High Velocity Therapy vs High Flow Nasal Cannula? The Ten Clinical Studies to Read

Vapotherm high velocity therapy often gets conflated with commodity high flow oxygen products, also commonly known as High Flow Nasal Cannula (HFNC). Many studies don’t differentiate between the two, though this is slowly changing in the medical field as randomized controlled trial evidence showed high velocity therapy to have outcomes.

Nebulized Hypertonic Saline Treatment for Bronchiolitis Shows No Difference in Outcomes vs Normal Saline

In August 2017, Angoulvant and colleagues published the results of a randomized controlled trial in JAMA Pediatrics titled “Effect of Nebulized Hypertonic Saline Treatment in Emergency Departments on the Hospitalization Rate for Acute Bronchiolitis”. The trial included 777 infants presenting in the Emergency Department with a first episode of acute bronchiolitis, but who were otherwise healthy.

Minimizing HAPIs from NIPPV

The National Pressure Ulcer Agency Advisory Panel (NPUAP) considers all patients with a medical device to be at risk for medical device related pressure injuries (MDRPIs). Interventions and successful minimization of hospital acquired pressure injuries (HAPIs) from non-invasive positive pressure ventilation (NIPPV) require specific assessment and prevention strategies and begin with a comprehensive multi-disciplinary approach and education program.

What are Hospital Acquired Pressure Injuries (HAPI) from NIPPV Costing Your Hospital?

Hospital Acquired Pressure Injuries (HAPI), also known as pressure ulcers, are often costly yet preventable events. To understand the impact of HAPI from noninvasive positive pressure ventilation (NIPPV) on your organization and to develop effective strategies for pressure injury reduction, it is important to understand how a pressure injury is defined and classified, what stages of pressure injuries cannot be reimbursed, how these types of injuries occur, and their frequency.

Hi-VNI® Technology Shows Similar Efficacy to nCPAP as Post-Extubation Support in Neonates

The results of the prospective, randomized controlled trial were published by Collins and colleagues in May 2013 in The Journal of Pediatrics titled “A Randomized Controlled Trial to Compare Heated Humidified High-Flow Nasal Cannulae with Nasal Continuous Positive Airway Pressure Postextubation in Premature Infants”.

Large Clinical Trial Confirms Safety & Efficacy of HFNC for Treating Bronchiolitis

The results of the prospective, multi-center randomized controlled trial were published by Franklin and colleagues in March 2018 in New England Journal of Medicine titled A Randomized Trial of High-Flow Oxygen Therapy in Infants with Bronchiolitis. The trial found among infants with bronchiolitis, those treated with high flow nasal cannula (HFNC) had significantly lower rates of escalation of care due to treatment failure than those treated with standard Oxygen therapy.